The FDA has just approved selegiline, which will be the first transdermal (skin) patch for use in the treatment of major depression in adults and will be sold under the trade name Emsam.
Discover The World's MOST COMPREHENSIVE Mental Health Assessment Platform
Efficiently assess your patients for 80+ possible conditions with a single dynamic, intuitive mental health assessment. As low as $12 per patient per year.
According to Dr. Steven Galson, Director of the Center for Drug Evaluation and Research (CDER), “Emsam provides a significant advance because at least in its lowest dose patients can use the drug without the usual dietary restrictions associated with these types of drugs known as MAO inhibitors.” Gotta just love it that Bristol-Meyers not only has great commercials but is coming with great products too!
More at USA Today…